At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 24 target
Drug / intervention
Azacitidine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
In Brief
A Phase 1 clinical trial evaluating Azacitidine and Rezatapopt for Myelodysplastic Syndrome and Acute Myeloid Leukemia. Currently recruiting, targeting 24 participants across 1 site.
Detailed Summary
A non-randomized phase Ib study of PC14586 (PMV therapeutics) in patients diagnosed with TP53Y220C-mutant myeloid malignancies, including AML and MDS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndrome, Acute Myeloid Leukemia
CountriesUnited States
Timeline
Phase 1Recruiting
20252026202720282029
First PostedSep 2024
Enrollment StartJan 2025
TodayJul 2026
Primary CompletionAug 2027
Study CompletionAug 2029
First PostedSep 27, 2024
Enrollment StartJan 30, 2025
Primary CompletionAug 27, 2027
Study CompletionAug 27, 2029
TodayJul 1, 2026
Enrollment to primary: 2.6 yearsPosted 1.8 years agoPrimary completion in 1.2 years
Interventions
Azacitidinedrug
Given by IV
Rezatapoptdrug
Given orally with food